BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy

Autor: Wiesweg, Marcel, Preuß, Cedric, Roeper, Julia, Metzenmacher, Martin, Eberhardt, Wilfried, Stropiep, Ursula, Wedeken, Katrin, Reis, Henning, Herold, Thomas, Darwiche, Kaid, Aigner, Clemens, Stuschke, Martin, Schildhaus, Hans-Ulrich, Schmid, Kurt W., Falk, Markus, Heukamp, Lukas, Tiemann, Markus, Griesinger, Frank, Schuler, Martin
Zdroj: In European Journal of Cancer May 2021 149:211-221
Databáze: ScienceDirect
Externí odkaz: